Abstract
Background Statins are currently the preferred agent for the treatment of hypercholesterolemia. However, myalgia, increased serum levels of creatinekinase (CK) and even rhabdomyolysis may occur, characterizing the cholesterol lowering agents myopathy (CLAM), with a multifactorial aetiology. In statin monotherapy, the incidence of CLAM is 0.1 to 0.5 % and is dose related. RYR1 (ryanodine 1) gene alteration was observed in the patients with CLAM, an animal model of MH (malignant hyperthermia) showed hyper metabolism after simvastatin, simvastatin induced in vitro contractures in muscle of animal model and susceptibility to MH by IVCT (in vitro contracture test) was diagnosed in patients with CLAM. On the other way, postoperative rhabdomyolysis occurred in patients treated with cholesterol-lowering drugs, leading to the suggestion of suspend these medications prior to surgery or do not use succinylcholine in patients taking these drugs . But this stance is challenged by other groups. Thus, this study examined, in rats chronically exposed to simvastatin dose previously associated with muscle alteration, the outcome of the IVCT.
Highlights
Statins are currently the preferred agent for the treatment of hypercholesterolemia
RYR1 gene alteration was observed in the patients with cholesterol - lowering agents myopathy (CLAM), an animal model of MH showed hyper metabolism after simvastatin, simvastatin induced in vitro contractures in muscle of animal model and susceptibility to MH by IVCT was diagnosed in patients with CLAM
Postoperative rhabdomyolysis occurred in patients treated with cholesterol-lowering drugs, leading to the suggestion of suspend these medications prior to surgery or do not use succinylcholine in patients taking these drugs
Summary
Chronic use of low dose simvastatin does not alter the IVCT in normal rats Pamela Vieira Andrade, Joilson Moura Santos, José Apolinário Silva Neves Junior, José Luiz Gomes do Amaral, Helga Cristina Almeida da Silva*. From 33rd Annual Meeting of the European Malignant Hyperthermia Group (EMHG) Würzburg, Germany. 15-17 May 2014
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
